According to findings from an 8-week study presented at the virtual Crohns and Colitis Congress, low doses of the recombinant T-cell growth factor interleukin 2 (IL-2) were tolerated well by patients with moderate-to-severe ulcerative colitis. Only one patient withdrewowing to a dose-limiting toxicity, reported an investigator.

About 38.4% of the patients enroled in the study achieved a clinical response and 15.4% were in clinical remission by week 8, reported Jessica R. Allegretti, MD, of Harvard University in Boston. Low-dose subcutaneous IL-2 was found to be well tolerated and yielded a biological response and peripheral Treg expansion among moderate-to-severe ulcerative colitis patients. The maximum effective dose was 1 x 106 IU/m2/day… (Medpage Today)